Enliven Therapeutics CFO sells 6,018 shares

The chief financial officer's option exercise and sales followed a Rule 10b5-1 plan adopted March 18, 2026.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. Chief Financial Officer Benjamin Hohl exercised 6,018 options on October 19, 2026, acquiring 6,018 common shares at a $14.85 exercise price, and reported a sale of 6,018 common shares at a weighted average price of $38.4755 per share. The exercise and sales were effected under a Rule 10b5-1 trading plan adopted March 18, 2026. The derivative line reports 175,000 shares underlying options following the transaction, with an expiration date of February 13, 2034.

Insider Trade Summary 10b5-1

Exercise and Sale: 6,018 shares ($142K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Hohl Benjamin

Role CHIEF FINANCIAL OFFICER

Sold 6,018 shs ($232K)

Approx. gross sale proceeds $232K

Approx. exercise cost $89K

Approx. pre-tax spread $142K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F4	6,018	$0.00	$0.00
Exercise	Common Stock F1, F2	6,018	$14.85	$89K
Sale	Common Stock F1, F3, F2	6,018	$38.4755	$232K

Holdings After Transaction: Stock Option (right to buy) — 175,000 contracts (Direct); Common Stock — 38,000 shares (Direct)

Footnotes (4)

1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. F3. This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 6,018 shares Exercise price: $14.85 per share Common shares sold: 6,018 shares +3 more

6 metrics

Options exercised 6,018 shares October 19, 2026

Exercise price $14.85 per share Options exercised on October 19, 2026

Common shares sold 6,018 shares October 19, 2026

Weighted average sale price $38.4755 per share Sale on October 19, 2026

Shares underlying options following transaction 175,000 shares Reported following the October 19, 2026 transaction

Original option size 185,000 shares Option described in the vesting footnote

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units (RSUs), vesting schedule

4 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"reflects the weighted average sale price"

restricted stock units (RSUs) financial

"securities are restricted stock units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vesting schedule financial

"subject to the applicable vesting schedule and conditions"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ELVN's CFO sell, and at what price?

Benjamin Hohl, Enliven Therapeutics' chief financial officer, sold 6,018 common shares on October 19, 2026, at a weighted average price of $38.4755 per share. The exercise and sales were effected under a Rule 10b5-1 trading plan adopted March 18, 2026.

At what prices were ELVN CFO Benjamin Hohl's sale trades executed?

The 6,018-share sale on October 19, 2026, was executed in multiple trades at prices ranging from $37.785 to $38.765; the reported weighted average sale price was $38.4755 per share.

How did Benjamin Hohl's ELVN option vest?

The option was originally for 185,000 shares. It vested as to one-fourth of the shares on February 13, 2025, and the remainder vests in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 05:54 PM EDT Accepted by SEC EDGAR 10/21/2026 - 05:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hohl Benjamin

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/19/2026		M(1)		6,018	A	$14.85	44,018(2)	D
Common Stock	10/19/2026		S(1)		6,018	D	$38.4755(3)	38,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.85	10/19/2026		M(1)			6,018	(4)	02/13/2034	Common Stock	6,018	$0	175,000	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.

	/s/ Benjamin Hohl	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)